Latest & greatest articles for ipratropium

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on ipratropium or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on ipratropium and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for ipratropium

1. Nebulized terbutaline & ipratropium bromide vs terbutaline alone in acute exacerbation of COPD requiring noninvasive ventilation: a randomized double blind controlled trial

Nebulized terbutaline & ipratropium bromide vs terbutaline alone in acute exacerbation of COPD requiring noninvasive ventilation: a randomized double blind controlled trial 30156361 2018 10 22 1553-2712 2018 Aug 29 Academic emergency medicine : official journal of the Society for Academic Emergency Medicine Acad Emerg Med Nebulized Terbutaline and Ipratropium Bromide Versus Terbutaline Alone in Acute Exacerbation of Chronic Obstructive Pulmonary Disease Requiring Noninvasive Ventilation (...) : A Randomized Double-blind Controlled Trial. 10.1111/acem.13560 Short-acting β 2 -agonists are the mainstay of treatment of patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) in the emergency department (ED). It is still unclear whether the addition of short-acting anticholinergics is clinically more effective care compared to treatment with β 2 -agonists alone in patients with hypercapnic AECOPD. The objective was to evaluate whether combining ipratropium bromide (IB

EvidenceUpdates2018

2. Ipratropium

Ipratropium Top results for ipratropium - Trip Database or use your Google+ account Liberating the literature My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for ipratropium The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines

Trip Latest and Greatest2018

3. Transient anisocoria in a patient treated with nebulized ipratropium bromide

Transient anisocoria in a patient treated with nebulized ipratropium bromide 29260071 2018 11 13 2451-9936 7 2017 Sep American journal of ophthalmology case reports Am J Ophthalmol Case Rep Transient anisocoria in a patient treated with nebulized ipratropium bromide. 11-13 10.1016/j.ajoc.2017.04.005 We present a case report of a 44-year old female patient with complicated pneumonia who developed anisocoria after treatment with inhaled ipratropium bromide. Discontinuation of ipratropium bromide (...) treatment led to complete resolution of anisocoria. A 44-year old female patient was admitted to the Department of Pulmonology due to high body temperature (40.0 °C), coughing and general weakness. After a general examination and tests the patient was diagnosed with right-sided pneumonia. Since spirometry test showed signs of bronchial obstruction, pulmonologist indicated inhalation therapy with ipratropium bromide. Soon after ipratropium bromide therapy was initiated, the patient noticed enlarged left

American journal of ophthalmology case reports2017 Full Text: Link to full Text with Trip Pro

6. Tiotropium compared with ipratropium for patients with moderate to severe chronic obstructive pulmonary disease: a review of the clinical effectiveness

Tiotropium compared with ipratropium for patients with moderate to severe chronic obstructive pulmonary disease: a review of the clinical effectiveness Tiotropium compared with ipratropium for patients with moderate to severe chronic obstructive pulmonary disease: a review of the clinical effectiveness Tiotropium compared with ipratropium for patients with moderate to severe chronic obstructive pulmonary disease: a review of the clinical effectiveness CADTH Record Status This is a bibliographic (...) record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Tiotropium compared with ipratropium for patients with moderate to severe chronic obstructive pulmonary disease: a review of the clinical effectiveness. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2012 Authors' conclusions Tiotropium appears to help improve objective lung function test measures, reduce

Health Technology Assessment (HTA) Database.2012

8. Nebulized Ipratropium for Asthma Attack

Nebulized Ipratropium for Asthma Attack Nebulized Ipratropium for Asthma Attack – TheNNTTheNNT Nebulized Ipratropium Given During an Asthma Attack 11 for prevented hospitalization In Summary, for those who received the ipratropium: Benefits in NNT 90.9% saw no benefit from adding ipraptropium during an asthma attack 9.1% were helped by preventing hospitalization 1 in 11 were helped (preventing hospitalization) Harms in NNT 0% were harmed by drug side effects None were harmed (serious side (...) effects) View As: NNT % Source: Efficacy Endpoints: Need for hospitalization Harm Endpoints: Medication side effects Narrative: Acute asthma exacerbation is responsible for an estimated 1.6 million emergency department visits and over 440,000 hospital admissions per year . The cornerstone of management remains aerosolized, short acting, β2-agonists and systemic corticosteroids . Anticholinergic agents such as ipratropium bromide, are effective bronchodilators, but comparative studies suggest

theNNT2012

9. Combivent Respimat (ipratropium bromide and albuterol) Inhalation Spray

Combivent Respimat (ipratropium bromide and albuterol) Inhalation Spray Drug Approval Package: Combivent Respimat (ipratropium bromide and albuterol) NDA #021747 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Combivent Respimat (ipratropium bromide and albuterol) Inhalation Spray Company: Boehringer Ingelheim Pharmaceutical, Inc. Application No.: 021747 Approval Date: 10/07/2011 Persons with disabilities having problems accessing the PDF files

FDA - Drug Approval Package2011

10. Economic analyses comparing tiotropium with ipratropium or salmeterol in UK patients with COPD

Economic analyses comparing tiotropium with ipratropium or salmeterol in UK patients with COPD Economic analyses comparing tiotropium with ipratropium or salmeterol in UK patients with COPD Economic analyses comparing tiotropium with ipratropium or salmeterol in UK patients with COPD Gani R, Griffin J, Kelly S, Rutten-van Molken M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study compared the cost-effectiveness of tiotropium, ipratropium, and salmeterol, for the treatment of chronic obstructive pulmonary disease. The authors concluded that tiotropium was a cost-effective alternative to ipratropium and salmeterol, and switching patients from ipratropium and salmeterol to tiotropium led to considerable cost savings

NHS Economic Evaluation Database.2010

11. Tiotropium compared with ipratropium for patients with moderate to severe chronic obstructive pulmonary disease: a review of the clinical effectiveness

Tiotropium compared with ipratropium for patients with moderate to severe chronic obstructive pulmonary disease: a review of the clinical effectiveness Tiotropium compared with ipratropium for patients with moderate to severe chronic obstructive pulmonary disease: a review of the clinical effectiveness Tiotropium compared with ipratropium for patients with moderate to severe chronic obstructive pulmonary disease: a review of the clinical effectiveness Pohar R, Nkansah E Record Status (...) This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Pohar R, Nkansah E. Tiotropium compared with ipratropium for patients with moderate to severe chronic obstructive pulmonary disease: a review of the clinical effectiveness. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2009 Authors' conclusions In two RCTs, patients with moderate to severe COPD who were

Health Technology Assessment (HTA) Database.2009

12. Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain

Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain Rutten-van Molken M P, Oostenbrink J B (...) inhaled anticholinergic), salmeterol (an inhaled beta-2-agonist) and ipratropium (a short-acting inhaled anticholinergic). Type of intervention Treatment. Economic study type Cost-effectiveness analysis and cost-utility analysis. Study population The study population comprised patients with stable moderate-to-severe COPD who had a forced expiratory volume in 1 second (FEV1) of less than 65% (salmeterol controlled trials < 60%) of predicted normal and 70% of forced vital capacity. In total, 1,308

NHS Economic Evaluation Database.2007

13. Drugs - Ipratropium Bromide (Atrovent)

Drugs - Ipratropium Bromide (Atrovent) Ipratropium Bromide (Atrovent) IPR Drugs October 2006 Page 1 of 1 Drugs PRESENTATION Nebules containing ipratropium bromide 250 micrograms in 1ml or 500 micrograms in 2ml. ACTIONS 1.Ipratropium bromide is an antimuscarinic bronchodilator drug. It may provide short term relief in acute asthma, but beta 2 agonists (such as salbutamol) generally work more quickly. Ipratropium should be considered in acute severe or life threatening asthma or in cases of acute (...) asthma or COPD which fail to improve with standard therapy (including salbutamol). 2. Ipratropium is considered of greater bene?t in: a. children suffering acute asthma. b. adults suffering with COPD. DOSAGE AND ADMINISTRATION CAUTIONS Ipratropium should be used with care in patients with: • glaucoma (protect the eyes from mist). • pregnancy and breastfeeding. INDICATIONS Acute severe or life threatening asthma (to be given concurrent with ?rst dose of salbutamol). Acute asthma unresponsive

Joint Royal Colleges Ambulance Liaison Committee2007

14. A smoking cessation programme plus inhaled ipratropium improved survival in asymptomatic airway obstruction

A smoking cessation programme plus inhaled ipratropium improved survival in asymptomatic airway obstruction A smoking cessation programme plus inhaled ipratropium improved survival in asymptomatic airway obstruction | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here A smoking cessation programme plus inhaled ipratropium improved survival in asymptomatic airway obstruction Article Text Therapeutics A smoking cessation programme plus inhaled ipratropium improved survival in asymptomatic airway obstruction Free John B Schorling , MD, MPH Statistics from

Evidence-Based Medicine (Requires free registration)2006

15. Ipratropium Bromide (Atrovent)

Ipratropium Bromide (Atrovent) Ipratropium Bromide (Atrovent) IPR Drugs October 2006 Page 1 of 1 Drugs PRESENTATION Nebules containing ipratropium bromide 250 micrograms in 1ml or 500 micrograms in 2ml. ACTIONS 1.Ipratropium bromide is an antimuscarinic bronchodilator drug. It may provide short term relief in acute asthma, but beta 2 agonists (such as salbutamol) generally work more quickly. Ipratropium should be considered in acute severe or life threatening asthma or in cases of acute asthma (...) or COPD which fail to improve with standard therapy (including salbutamol). 2. Ipratropium is considered of greater bene?t in: a. children suffering acute asthma. b. adults suffering with COPD. DOSAGE AND ADMINISTRATION CAUTIONS Ipratropium should be used with care in patients with: • glaucoma (protect the eyes from mist). • pregnancy and breastfeeding. INDICATIONS Acute severe or life threatening asthma (to be given concurrent with ?rst dose of salbutamol). Acute asthma unresponsive to salbutamol

Joint Royal Colleges Ambulance Liaison Committee2006

16. An economic assessment of inhaled formoterol dry powder versus ipratropium bromide pressurized metered dose inhaler in the treatment of chronic obstructive pulmonary disease

An economic assessment of inhaled formoterol dry powder versus ipratropium bromide pressurized metered dose inhaler in the treatment of chronic obstructive pulmonary disease An economic assessment of inhaled formoterol dry powder versus ipratropium bromide pressurized metered dose inhaler in the treatment of chronic obstructive pulmonary disease An economic assessment of inhaled formoterol dry powder versus ipratropium bromide pressurized metered dose inhaler in the treatment (...) powder 12 microg twice a day, inhaled formoterol dry powder 24 microg twice a day and ipratropium bromide 4 microg four times a day in a pressurised metered dose inhaler. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients with COPD. Specific inclusion/exclusion criteria were not reported. Setting The setting was not clearly stated but it is likely to have been primary and secondary care. The economic study

NHS Economic Evaluation Database.2003

17. Tiotropium: a potential replacement for ipratropium in patients with COPD

Tiotropium: a potential replacement for ipratropium in patients with COPD Tiotropium: a potential replacement for ipratropium in patients with COPD Tiotropium: a potential replacement for ipratropium in patients with COPD Shukla V K Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Shukla V K. Tiotropium: a potential replacement (...) for ipratropium in patients with COPD. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA) 2002: 4 Authors' objectives To summarise the available evidence on tiotropium as a potential replacement for ipratropium in patients with chronic obstructive pulmonary disease. Authors' conclusions - Inhaled tiotropium provides a sustained bronchodilator effect over a 24-hour period in patients with chronic obstructive pulmonary disease (COPD). - There is some evidence that tiotropium 18g once

Health Technology Assessment (HTA) Database.2002

18. Inhaled short-acting beta2-agonists versus ipratropium for acute exacerbations of chronic obstructive pulmonary disease.

Inhaled short-acting beta2-agonists versus ipratropium for acute exacerbations of chronic obstructive pulmonary disease. BACKGROUND: Inhaled short acting beta2 adrenergic agonists and ipratropium bromide are both used in the treatment of acute exacerbations of chronic obstructive pulmonary disease. OBJECTIVES: In patients with acute exacerbations of COPD to: 1. To assess the efficacy of short-acting beta-2 agonists against placebo; 2. Compare the efficacy of short-acting beta-2 agonists (...) and ipratropium. SEARCH STRATEGY: A comprehensive search of the literature was carried out of EMBASE, MEDLINE, CINAHL and the Cochrane COPD trials register was carried out using the terms: bronchodilator* OR albuterol OR metaproterenol OR terbutaline OR isoetharine OR pirbuterol OR salbutamol OR beta-2 agonist. SELECTION CRITERIA: All trials that appeared to be relevant were assessed by two reviewers who independently selected trials for inclusion. Differences were resolved by consensus. DATA COLLECTION

Cochrane2001

19. A meta-analysis of the effects of ipratropium bromide in adults with acute asthma

A meta-analysis of the effects of ipratropium bromide in adults with acute asthma A meta-analysis of the effects of ipratropium bromide in adults with acute asthma A meta-analysis of the effects of ipratropium bromide in adults with acute asthma Rodrigo G, Rodrigo C, Burschtin O Authors' objectives To determine whether inhaled ipratropium bromide provides additional benefits to adults with acute asthma, who are being treated with beta-agonists in an emergency department. Searching MEDLINE (...) was searched from 1978 to April 1999 using the following MeSH terms: 'N-isopropylatropine' or 'ipratropium bromide', and 'adult', 'acute asthma' or status asthmaticus'. Searches of Current Contents, the Science Citation Index, and review articles were also performed. Studies were limited to those published in the English language. Details of additional published and unpublished studies were obtained by contacting experts (pulmonologists and emergency physicians) and the manufacturer of ipratropium bromide

DARE.1999

20. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD

Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD Friedman M, Serby C W, Menjoge S S, Wilson J D, Hilleman D E, Witek T J Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Pharmaceutical technology: ipratropium combined with albuterol in a single inhalational canister (Combivent; Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, USA). Type of intervention Treatment. Economic

NHS Economic Evaluation Database.1999